BLAINJECTIONINJECTABLE
Approved
Apr 2019
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
2/8 — Basic
IRA Negotiated
Drug data last refreshed 8h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ETICOVO (etanercept-ykro) is a biosimilar fusion protein that mimics the mechanism of the reference biologic etanercept, a TNF-α inhibitor used primarily in autoimmune and inflammatory diseases. It binds tumor necrosis factor-alpha, reducing immune-mediated inflammation across multiple therapeutic areas. The drug is administered via injection and represents Samsung Bioepis's entry into the competitive TNF inhibitor biosimilar market.
Peak
ETICOVO is at peak commercial maturity post-2019 approval with established market presence; teams are optimizing managed care access and defending share against price compression from IRA negotiation.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
Samsung Bioepis is hiring 5 roles related to this product
Worked on ETICOVO at Samsung Bioepis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.